Evidence map›Paper›PMID 36419093›Full record

ArticleArthritis research & therapy2022

Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage.

Qixing Li, Yanpeng Li, Bibo Liang, Rui Xu, Bingze Xu, Erik Lönnblom, Hui Feng, Jing'an Bai, Roma Stawikowska, Changrong Ge and 4 more

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Qixing LiCenter for Medical Immunopharmacology Research, Southern Medical University, Guangzhou, China.
Yanpeng LiCenter for Medical Immunopharmacology Research, Southern Medical University, Guangzhou, China.
Bibo LiangCenter for Medical Immunopharmacology Research, Southern Medical University, Guangzhou, China.
Rui XuCenter for Medical Immunopharmacology Research, Southern Medical University, Guangzhou, China.
Bingze XuSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Biomedicum, Quarter 9D, 171 65, Solna, Sweden.
Erik LönnblomSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Biomedicum, Quarter 9D, 171 65, Solna, Sweden.
Hui FengGuanghua Integrative Medicine Hospital, Changning District, Shanghai, China.
Jing'an BaiInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Roma StawikowskaDepartment of Chemistry & Biochemistry and I-HEALTH, Florida Atlantic University, Jupiter, FL, USA.
Changrong GeSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Biomedicum, Quarter 9D, 171 65, Solna, Sweden.
Aiping LuInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Gregg B FieldsDepartment of Chemistry & Biochemistry and I-HEALTH, Florida Atlantic University, Jupiter, FL, USA.
Lianbo XiaoGuanghua Integrative Medicine Hospital, Changning District, Shanghai, China.
Rikard HolmdahlCenter for Medical Immunopharmacology Research, Southern Medical University, Guangzhou, China. Rikard.Holmdahl@ki.se.
Karolinska Institutet · SESouthern Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFlorida Atlantic University · USShanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

Autoantibody modulation of cartilage turnover in rheumatoid arthritisR15AI154248 · NIAID · FLORIDA ATLANTIC UNIVERSITY · PI FIELDS, GREGG B · 2021 to 2021
$429k
NIAID NIH HHS R15 AI154248
6 · The paper itself

Abstract

objectiveTo investigate the occurrence and frequency of anti-citrullinated protein antibodies (ACPA) to cyclic citrullinated type II collagen (COL2) epitope with a capacity to bind joint cartilage.

methodsLuminex immunoassay was used to analyze serum antibody reactivity to 10 COL2-citrullinated peptides (ACC10) and corresponding arginine peptide controls in rheumatoid arthritis (RA), osteoarthritis (OA), and healthy individuals' cohorts. Top ten "promiscuous" sera (cross-reactive with all ACC10) and top ten "private" sera (restrictedly reactive with one ACC10 peptide) from RA and OA cohorts were selected. Enzyme-linked immunosorbent assay (ELISA) was used to detect response to native COL2. Sera were analyzed with naive and arthritic joints from DBA/1J mice by immunohistochemistry, using monoclonal ACPAs and COL2 reactive antibodies with human Fc as comparison. Staining specificity was confirmed with C1 (a major antibody epitope on COL2) mutated mice and competitive blocking with epitope-specific antibodies.

resultsAll patient sera bound ACC10 compared with control peptides but very few (3/40) bound native triple-helical COL2. Most sera (27/40) specifically bound to arthritic cartilage, whereas only one private RA serum bound to healthy cartilage. Despite very low titers, private sera from both RA and OA showed an epitope-specific response, documented by lack of binding to cartilage from C1-mutated mice and blocking binding to wild-type cartilage with a competitive monoclonal antibody. As a comparison, monoclonal ACPAs visualized typical promiscuous, or private reactivity to joint cartilage and other tissues.

conclusionACPA from RA and OA sera, reactive with citrullinated non-triple-helical COL2 peptides, can bind specifically to arthritic cartilage.

Indexed as

Arthritis, RheumatoidOsteoarthritisAminosalicylic AcidsAnimalsAutoantibodiesCartilageCollagen Type IIEpitopesHumansMiceMice, Inbred DBAMyeloblastinacetyl 4-aminosalicylic acidAminosalicylic AcidsAutoantibodiesCollagen Type IIEpitopesMyeloblastinAnti-citrullinated type II collagen antibodiesOsteoarthritisRheumatoid arthritis

Identifiers

PMID36419093
PMCPMC9682822
OpenAlexW4309700404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.